What is cancer chemotherapy?

References

• Gilman A. The initial clinical trial of nitrogen mustard. Am J Surgery 1963; 105: 574–8.
   PubMed Web of Science ®Google Scholar
• Pratt W, Ruddon R. The anticancer drugs. New York: Ox-ford University Press, 1979.
   Google Scholar
• O'Dwyer PJ, Johnson SW, Hamilton TC. Cisplatin and its analogues. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology, 5th edn. Philadelphia: Lippincott-Raven Publishers, 1997: 418–32.
   Google Scholar
• Verweij J, Clavel M, Chevalier B. Paclitaxel and docetaxel: not simply two of a kind. Ann Oncol 1994; 5: 495–505.
   Google Scholar
• Dancey J, Eisenhauer E. Current perspectives on camp-tothecins in cancer treatment. Br J Cancer 1996; 74: 327–38.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Miscellaneous chemotherapeutic agents. In: De-Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology, 5th edn. Philadelphia, Lippincott-Raven Publishers, 1997: 490–8.
   Google Scholar
• DeVita VT Jr. Principles of cancer manangement: chemother-apy. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology, 5th edn. Philadelphia: Lippincott-Raven Publishers, 1997: 333–49.
   Web of Science ®Google Scholar
• Csoka K. The Fluorometric Microculture Cytotoxicity Assay (FMCA) in assessment of the clinical activity cytotoxic drugs. Dissertations Uppsala University, Uppsala 1997: pp 80.
   Google Scholar
• Nygren P, Glimelius B. The Swedish Council on Technology Assessment in Health Care (SBU) report on cancer chemotherapy-Project objectives, the working process, key definitions and general aspects on cancer trial methodology and interpretation. Acta Oncol 2001; 40: 155–65.
   PubMed Web of Science ®Google Scholar
• Multiple authors: Pharmacology of Cancer Chemotherapy. In: DeVita Jr VT; Hellman S; Rosenberg S, (eds) Cancer. Principles and Practice of Oncology, 5th edn. Philadelphia, Lippincott-Raven Publishers, 1997: 375–513.
   Google Scholar
• Beck WT, Dalton WS. Mechanisms of drug resistance. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology, 5th edn. Philadelphia: Lippicottt-Raven Publishers, 1997: 498–513.
   Google Scholar
• Hickman JA. Genes that modulate apoptosis: major determi-nants of drug resistance. In: Pinedo HM, Giaccone G, eds. Drug resistance in the treatment of cancer. Cambridge: Cam-bridge University Press, 1998: 178–99.
   Google Scholar
• Thornberry NA, Lazebnik Y. Caspases: enemies within. Sci-ence 1998; 281: 1312–6.
   PubMed Web of Science ®Google Scholar
• Constenla DO, Hill ME, A'Hern RP, et al. Chemotherapy for symptom control in recurrent squamos cell carcinoma of the head and neck. Ann Oncol 1997; 8: 445–9.
   Google Scholar
• Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 1993; 4: 235–41.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Hoffman K, Palman L, et al. Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide antigen specific (TPS) measure-ments. Acta Oncol 1996; 35: 141–8.
   PubMed Web of Science ®Google Scholar
• Nelson K, Walsh D, Sheehan F. The cancer anorexia-cachexia syndrome. J Clin Oncol 1994; 12: 213–25.
   PubMed Web of Science ®Google Scholar
• Sandstrom M, Freijs A, Larsson R, et al. Lack of relationship between systemic exposure for the component drugs of the fluorouracil, epirubicin and 4-hydroxocyclophosphamide regi-men in breast cancer patients. J Clin Oncol 1996; 14: 1581–8.
   PubMed Web of Science ®Google Scholar
• Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14: 2590–611.
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualised chemotherapy for childhood acute lymphoblastic leukaemia. N Engl J Med 1998; 338: 494–505.
   Web of Science ®Google Scholar
• Morrow C, Cowan K. Drug resistance and cancer. In: Yang S, Warner H, eds. The underlying molecular, cellular an immunological factors in cancer and aging. New York: Plenum Press, 1993: 287–305.
   Google Scholar
• Larsson R, Nygren P. Laboratory prediction of clinical chemotherapeutic drug resistance: a working model exem-plified by acute leukaemia. Eur J Cancer 1993; 29A: 1208–12.
   PubMed Web of Science ®Google Scholar
• Tannock IF. Cell proliferation. In: Tannock IF, Hill RP, eds. The Basic Science of Oncology. New York: McGraw-Hill, 1992: 154–78.
   Google Scholar
• Preisler HD, Kotelnikov VM, LaFollette S, et al. Continued malignant cell proliferation in head and neck tumours during cytotoxic therapy. Clin Cancer Res 1996; 2: 1453–60.
   PubMed Web of Science ®Google Scholar
• Nygren P, Fridborg H, Csoka K, et al. Detection of tumour specific cytotoxic drug activity in vitro using the fluorometric microculture cyto toxicity assay and primary cultures of tu-mour cells from patients. Int J Cancer 1994; 56: 715–20.
   PubMed Web of Science ®Google Scholar
• Beck WT. The cell biology of multiple drug resistance. Biochem Pharamcol 1987; 36: 2879–87.
   PubMed Web of Science ®Google Scholar
• Ford J, Hait W. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 156–99.
   Web of Science ®Google Scholar
• Cole SP, Chanda ER, Dickie FP, et al. Non-P-glycoprotein mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 1991; 51: 689–704.
   Web of Science ®Google Scholar
• Botling J, Larsson R, Liminga G, et al. Development of vincristine resistance and increased sensitivitiy to cyclosporin A and verapamil in the human U-937 lymphoma cell line is not associated with expression of the 170 kD P-glycoprotein. Int J Cancer 1994; 58: 269–74.
   PubMed Web of Science ®Google Scholar
• Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994; 54: 4313–20.
   PubMed Web of Science ®Google Scholar
• Harris CC. Structure and function of the p53 tumour suppres-sor gene: clues for rational cancer therapeutic strategies. J Natl Ca Inst 1996; 88: 1442–55.
   PubMed Web of Science ®Google Scholar
• Desoize B, Robert J. Individual dose adaptation of anticancer drugs. Eur J Cancer 1994; 30A: 844–51.
   PubMed Web of Science ®Google Scholar
• Connors TA. Is there a future role for cancer chemotherapy. Ann Oncol 1996; 7: 445–52.
   PubMed Web of Science ®Google Scholar
• Hrushesky WJM, Bjamason GA. Circadian cancer therapy. J Clin Oncol 1993; 11: 1403–7.
   PubMed Web of Science ®Google Scholar
• Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330: 827–38.
   PubMed Web of Science ®Google Scholar
• Fruehauf JP, Bosanquet AG. In vitro determination of drug response: a discussion of clinical applications. PPO updates 1993; 7: 1–16.
   Google Scholar
• Raderer M, Scheithauer W. Clinical trials of agents that reverse multidrug resistance. Cancer 1993; 72: 3553–63.
   PubMed Web of Science ®Google Scholar
• Fridborg H, Jonsson B, Nygren P, et al. Activity of cyclo-sporins as resistance modifiers in primary cultures of human hematolgical and solid tumours. Br J Cancer 1994; 70: 11–7.
   PubMed Web of Science ®Google Scholar
• Hickman JA. Apoptosis induced by anticancer drugs. Cancer Met Rev 1992; 11: 121–39.
   PubMed Web of Science ®Google Scholar
• Boyd M. The future of new drug development. In: Neiderhu-ber J, ed. Current therapy in oncology. Philadelphia: Decker, B.C., Inc, 1993: 11–22.
   Google Scholar
• Cavallin-Stal E, Seiving B. Cytostatikamanual 1993, Lund 1992.
   Google Scholar
• Arbetarskyddsstyrelsen.Arbetarskyddsstyrelsensförfat-tningssamling: cytostatika. Solna, Publikationsservice 1984.
   Google Scholar
• Sessink PJM, van de Kerkhof CA, Anzion RBM, et al. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: Is skin absorption an important exposure route? Arch Environment Health 1994; 49: 165–9.
   PubMed Web of Science ®Google Scholar
• Sessink PJM, Cernd M, Rössner P, et al. Urinary cyclophos-phamide excretion and chromosomal aberrations in periph-eral blood lymphocytes after occupational exposure to antineoplastic agents. Mutations Res 1994; 309: 193–9.
   Google Scholar